GMED · NYSE · STOCK
Globus Medical (GMED) Stock Analysis
$74.68
52W $56.66 – $101.40
66/100
$10.07B
18.8
0.96
Is GMED Bullish or Bearish?
Bullish.
Innellis AI committee rates Globus Medical (GMED) Buy with a composite score of 66/100
, based on 6 analysts with 83% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.35 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.65 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 50.9% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- EPS growing 50.9% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price structure making lower highs and lower lows — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
66/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 2%
of 192 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 50.9% YoY
Technical Analyst
neutral
52
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.7 to 65.7.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
47.2
Neutral
MACD Histogram
0.207
Bullish Momentum
Trend Direction
Downtrend
Weekly: Sideways
Market Structure
Mixed
Support
$74.48
Resistance
$75.00
Bollinger %B
0.46
Inside Bands
Price vs Moving Averages
EMA 9
$74.79
Below
EMA 21
$75.54
Below
EMA 50
$77.52
Below
EMA 200
$79.98
Below
Fundamental Analysis
Valuation
92
Growth
85
Profitability
86
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
18.8×
P/B Ratio
2.12×
PEG Ratio
0.36
Dividend Yield
0.00%
52W High
$101.40
52W Low
$56.66
Quality & Growth
ROE
1176.2%
ROA
1014.4%
Gross Margin
6854.8%
Operating Margin
2075.4%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
P/E ratio of 18.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.1x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.8%; Return on assets of 10.1%; Net margin of 17.0%; Gross margin of 68.5%; Current ratio of 4.62 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is positive (5.54); Most recent quarter beat estimates by 19.5%; 5 consecutive earnings beats; EPS growth accelerating (-12.5% -> +19.6% QoQ); Average YoY EPS growth of 55.8%; Analyst estimates falling over recent quarters
Get the Full GMED Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →